Latest Conference Articles

Neratinib Combos Show Promise in HER2-Mutant Metastatic Breast Cancers

Neratinib (Nerlynx) induced positive overall response rates in patients with heavily pretreated hormone receptor–positive/HER2-negative, HER2-mutant metastatic breast cancer when combined with fulvestrant and trastuzumab, and also in patients with metastatic HER2-mutant triple-negative breast cancer when combined with trastuzumab.

Dr. Bardia on the Efficacy Results of the EMERALD Trial in ER+/HER2- Breast Cancer

Aditya Bardia, MD, MPH, discusses the efficacy results of the phase 3 EMERALD trial in estrogen receptor–positive, HER2-negative metastatic breast cancer.

AEs Related to Olaparib Treatment May Be Easily Mitigated in High-Risk Early Breast Cancer

Certain adverse effects associated with olaparib were minimal and resolved with appropriate management in patients with germline BRCA1/2 mutations in patients with high-risk, HER2-negative, early-stage breast cancer.

Likelihood of Pathologic CR After Neoadjuvant Chemo is Not Significantly Affected by Race in Breast Cancer

Pathologic complete response and event-free survival was not found to be significantly affected by race among patients with high-risk breast cancer who received neoadjuvant chemotherapy; however, disparities were observed among patients who did not achieve a pCR.

Dr. Ganz on the Quality of Life Results From the OlympiA Trial in BRCA-Mutated Breast Cancer

Patricia A. Ganz, MD, discusses the quality of life results from the phase 3 OlympiA trial in BRCA-mutated breast cancer.

Dr. Kruse on the Results of a Study Comparing Outcomes in Pleomorphic Vs Non-Pleomorphic Invasive Lobular Carcinoma

Megan Kruse, MD, discusses the results of a study comparing clinical features and outcomes of pleomorphic vs non-pleomorphic invasive lobular carcinoma.

Samuraciclib Plus Fulvestrant Improves PFS in Heavily Pretreated HR+ Breast Cancer

Fulvestrant plus the CDK7 inhibitor samuraciclib demonstrated encouraging efficacy in patients with hormone receptor-positive breast cancer who were heavily pretreated with CDK4/6 inhibitors.

Liso-cel Improves HRQoL Over Standard of Care in Relapsed/Refractory LBCL

Second-line lisocabtagene maraleucel demonstrated a favorable improvement in most patient-reported outcome domains compared with standard of care in patients with relapsed or refractory large B-cell lymphoma, and health-related quality of life was found to either be improved or maintained following treatment with the CAR T-cell therapy.

Early Use of ctDNA Testing Can Identify Likelihood of Relapse in TNBC

Physicians treating patients with early-stage triple-negative breast cancer should employ circulating tumor DNA testing early and often, according to results from the phase 2 cTRAK TN trial.

Subgroup Analyses Support T-DXd as Second-Line Standard in HER2+ Metastatic Breast Cancer

Trastuzumab deruxtecan led to prolonged progression-free survival and higher responses vs trastuzumab emtansine as second-line therapy in patients with HER2-positive metastatic breast cancer across all patients subgroups, including those with and without baseline brain metastases.

Dr. Schmid on Additional Results From the KEYNOTE-522 Trial in Early-Stage TNBC

Peter Schmid, MD, PhD, FRCP, discusses additional results from the phase 3 KEYNOTE-522 trial in early-stage triple-negative breast cancer.

Dr. Hurvitz on the Results of Subgroup Analyses From DESTINY-Breast03 in HER2+ Breast Cancer

Sara A. Hurvitz, MD, discusses the results of subgroup analyses from the phase 3 DESTINY-Breast03 trial in patients with HER2-positive metastatic breast cancer.

Pyrotinib Plus Capecitabine Shows Improved OS Over Lapatinib in HER2+ Breast Cancer

Pyrotinib plus capecitabine exhibited longer overall survival (OS), compared with lapatinib plus capecitabine, in patients with HER2-positive breast cancer

ASH 2021 Is Packed With Practice-Changing Hematologic Cancer Data

Not only is the 2021 ASH Annual Meeting bursting with more than 5000 abstracts unveiling pivotal data across a range of hematologic malignancies and disorders, but the conference will be held as a hybrid format after going fully virtual in 2020.

Efficacy of Pertuzumab/Trastuzumab Deruxtecan Combo Under Investigation in DESTINY-Breast09 for HER2+ Breast Cancer

Prior research has shown that the combination of trastuzumab deruxtecan plus pertuzumab may be superior to T-trastuzumab deruxtecan alone in patients with HER2-positive metastatic breast cancer and the combination is now under examination in the phase 3 DESTINY-Breast09 trial.

Adjuvant Approaches Reduce Risk of Distant Recurrence in HER2+ Early Stage Breast Cancer

Adjuvant treatment with neratinib or ado-trastuzumab emtansine resulted in a greater reduction in the risk of disease recurrence compared with other therapies in an epidemiologic model of HER2-positive, early-stage breast cancer.

Zanidatamab/Chemo Showcases Early Safety, Antitumor Activity in HER2+ Breast Cancer

The addition of the bispecific antibody zanidatamab to single-agent chemotherapy was found to produce promising antitumor activity with acceptable tolerability in heavily pretreated patients with HER2-positive breast cancer.

Addition of Chemo to Endocrine Therapy Yields Survival Benefit in Premenopausal HR+/HER2- Breast Cancer

Significant outcome differences were observed in premenopausal vs postmenopausal patients with hormone receptor–positive, HER2-negative breast cancer who had 1 to 3 positive lymph nodes and received adjuvant chemotherapy as well as endocrine therapy.

Tucatinib Plus Palbociclib/Letrozole Prolongs CNS-PFS in HR+/HER2+ Breast Cancer

A non-chemotherapy–based targeted regimen comprised of tucatinib, palbociclib, and letrozole resulted in prolonged central nervous system progression-free survival in patients with hormone receptor–positive, HER2-positive breast cancer.

Aromatase Inhibitors Significantly Reduce Recurrence in Premenopausal ER+ Breast Cancer

Aromatase inhibitors significantly reduced the risk of breast cancer recurrence in premenopausal women with estrogen receptor–positive breast cancer receiving ovarian suppression compared with tamoxifen.

Higher Incidence of Treatment Modifications Confers Worse Outcomes for Black Patients With Breast Cancer

Black patients with breast cancer were more likely to experience treatment modifications or discontinuations in the neoadjuvant setting compared with White patients.

Dr. Kalinsky on Updated Results From the RxPONDER Trial in HR+/HER2- Breast Cancer

Kevin Kalinsky, MD, MS, discusses updated results from the phase 3 RxPONDER trial in patients with hormone receptor-positive, HER2-negative breast cancer.

Frontline Ribociclib/Letrozole Improves OS in Postmenopausal HR+ Breast Cancer, Irrespective of Metastatic Site

First-line treatment with ribociclib/letrozole improved overall survival over placebo in patients with postmenopausal, hormone receptor–positive, HER2-negative advanced breast cancer, irrespective of metastatic site, number of sites, or prior (neo)adjuvant chemotherapy and endocrine therapy.

Standard IHC Assays Show Poor Accuracy in Identifying Low HER2 Expression in Breast Cancer

Survey data collected from more than 1400 laboratories around the world have demonstrated poor agreement in the evaluation of patients with breast cancer who have a low HER2 immunohistochemistry score of 0 or 1+ using standard HER2 assays.

Higher Oncotype DX Scores Predict for Improved Endocrine Therapy Compliance in ER+ Breast Cancer

Higher Oncotype DX recurrence scores were associated with prolonged persistence to 5 years of endocrine therapy vs lower Oncotype DX recurrence scores in patients with low-risk, estrogen receptor-positive/progesterone receptor–positive breast cancer, according to findings from a retrospective review.

Dr. Fernandez on the Results of a Study Examining Low HER2 Expression in Breast Cancer

Aileen I. Fernandez, PhD, discusses the results of a study examining low HER2 expression in breast cancer.

Datopotamab Deruxtecan Produces Encouraging Clinical Activity in Advanced TNBC

Datopotamab deruxtecan showed highly encouraging and durable efficacy through overall response rates in patients with advanced or metastatic triple-negative breast cancer.

Entinostat/Exemestane Improves PFS in Chinese Patients With Advanced HR+ Breast Cancer

The combination of entinostat and exemestane led to a significant improvement in progression-free survival compared with placebo and exemestane in Chinese patients with advanced hormone receptor–positive breast cancer.

Adjuvant Pembrolizumab Sustains Benefit Across TNBC Subgroups

Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab resulted in a statistically significant and clinically meaningful improvement in event-free survival in patients with early-stage triple negative breast cancer.

Final Results from PALLAS Study Confirm Lack of Benefit in Adding Palbociclib to ET in Early HR+, HER2- Breast Cancer

Adding adjuvant palbociclib to standard endocrine therapy did not improve outcomes in patients with stage II to III hormone receptor–positive, HER2-negative early breast cancer.